Joseph A Lewnard
Overview
Explore the profile of Joseph A Lewnard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
2968
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mendelson M, Lewnard J, Sharland M, Cook A, Pouwels K, Alimi Y, et al.
Lancet
. 2024 May;
403(10443):2551-2564.
PMID: 38797179
Rising antimicrobial resistance (AMR) is a global health crisis for countries of all economic levels, alongside the broader challenge of access to antibiotics. As a result, development goals for child...
12.
Fukui N, Li S, DeGuzman J, Myers J, Openshaw J, Sharma A, et al.
PLoS One
. 2024 May;
19(5):e0301070.
PMID: 38771784
Objective: To describe the implementation of a test-negative design case-control study in California during the Coronavirus Disease 2019 (COVID-19) pandemic. Study Design: Test-negative case-control study. Methods: Between February 24, 2021...
13.
Lewnard J, Mahale P, Malden D, Hong V, Ackerson B, Lewin B, et al.
medRxiv
. 2024 May;
PMID: 38699313
The SARS-CoV-2 BA.2.86 lineage, and its sublineage JN.1 in particular, achieved widespread transmission in the US during winter 2023-24. However, the increase in infections was not accompanied by increases in...
14.
Head J, Collender P, Leon T, White L, Sud S, Camponuri S, et al.
JAMA Netw Open
. 2024 Apr;
7(4):e247822.
PMID: 38652476
Importance: A SARS-CoV-2 vaccine was approved for adolescents aged 12 to 15 years on May 10, 2021, with approval for younger age groups following thereafter. The population level impact of...
15.
King L, Andrejko K, Kabbani S, Tartof S, Hicks L, Cohen A, et al.
J Infect Dis
. 2024 Mar;
230(4):821-831.
PMID: 38498565
Background: In 2022-2023, 15- and 20-valent pneumococcal conjugate vaccines (PCV15/PCV20) were recommended for infants. We aimed to estimate the incidence of outpatient visits and antibiotic prescriptions in US children (≤17...
16.
Brennhofer S, Platts-Mills J, Lewnard J, Liu J, Houpt E, Rogawski McQuade E
PLoS Med
. 2023 Nov;
20(11):e1004271.
PMID: 37992134
Background: Shigella is a leading cause of diarrhea and dysentery in children in low-resource settings, which is frequently treated with antibiotics. The primary goal of a Shigella vaccine would be...
17.
Snyder R, Saadeh K, Tang E, Johnson K, Holland S, Quint J, et al.
J Infect Dis
. 2023 Oct;
229(Supplement_2):S188-S196.
PMID: 37820738
Background: Exposures associated with mpox infection remain imperfectly understood. Methods: We conducted a case-control study enrolling participants who received molecular tests for mpox/orthopoxvirus in California from November 2022 through June...
18.
Bruxvoort K, Fischer H, Lewnard J, Hong V, Pomichowski M, Grant L, et al.
Pneumonia (Nathan)
. 2023 Oct;
15(1):15.
PMID: 37794443
Background: Respiratory pathogens, including SARS-CoV-2, can cause pulmonary structural damage and physiologic impairment, which may increase the risk of subsequent lower respiratory tract infections (LRTI). Prior hospitalization for any reason...
19.
King L, Andrejko K, Kabbani S, Tartof S, Hicks L, Cohen A, et al.
medRxiv
. 2023 Sep;
PMID: 37662372
Importance: is a known etiology of acute respiratory infections (ARIs), which account for large proportions of outpatient visits and antibiotic use in children. In 2023, 15- and 20-valent pneumococcal conjugate...
20.
Lewnard J, Hong V, Kim J, Shaw S, Lewin B, Takhar H, et al.
Nat Commun
. 2023 Jun;
14(1):3854.
PMID: 37386005
Host immune responses are a key source of selective pressure driving pathogen evolution. Emergence of many SARS-CoV-2 lineages has been associated with enhancements in their ability to evade population immunity...